Retatrutide peptide USA price: why you legally can't purchase it yet

Last updated 2026-07-25

Can you legally obtain retatrutide in the USA right now?

No. There is no legal channel to get retatrutide in the United States for personal use, at any price, from any source. A search of Drugs@FDA, the government's own database of approved drug products, returns nothing for the generic name retatrutide ^[1]. Under 21 U.S.C. 355, a new drug cannot be introduced into interstate commerce without an approved application, and retatrutide has none ^[2]. That single fact is the whole story behind every retatrutide search result you've seen promising a quick purchase. What you'll find instead are gray-market websites selling vials labeled "research use only" or "not for human consumption." Those disclaimers do not make the sale legal. They're a liability shield for the seller, not a green light for you. FDA has already acted against at least one peptide seller on exactly this point, which we cover below. If you're comparing this to semaglutide or tirzepatide, the difference is stark: those drugs cleared FDA review and are sold as OZEMPIC, WEGOVY, MOUNJARO, and ZEPBOUND ^[1]. Retatrutide hasn't cleared that bar. It's still in trials.

Why isn't there a compounding pathway, like there is for other peptides?

Compounding pharmacies (503A) can only use a bulk drug substance if it clears a strict three-step legal cascade under 21 U.S.C. 353a(b)(1)(A)(i): first, it must comply with a USP or NF monograph if one exists; second, if no monograph exists, it must be a component of an FDA-approved drug; third, only if neither of those applies can it come from the FDA's 503A Bulks List ^[3]. Retatrutide fails all three tests. There's no USP monograph for it, it isn't a component of any approved drug, and it is not on the Bulks List. The current 503A Bulks List, published at 21 CFR 216.23, contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[4]. None of them is a peptide. Retatrutide isn't on it, and neither is any GLP-1/GIP/glucagon peptide. There's a separate list for outsourcing facilities (503B), at 21 CFR 216.24, that governs larger-scale compounders. Retatrutide isn't on that one either ^[5]. So whether you're talking about a corner compounding pharmacy or a big 503B outsourcing facility, the legal door is shut on both sides. Even if a substance somehow qualified under the cascade, 503A separately requires that any bulk drug substance come from a facility registered under FD&C Act section 510 and ship with a valid certificate of analysis ^[3]. Research-use-only material from unregistered overseas suppliers fails this requirement regardless of anything else. That's a second, independent reason gray-market vials aren't lawful compounding inputs, even in the hypothetical world where retatrutide passed the ingredient test.

Has retatrutide ever been nominated for the compounding Bulks List?

No. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to consider seven peptides for possible addition to the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[6]. Retatrutide was not among them and has never been nominated for that list ^[6]. Even for the peptides that were considered, a favorable committee vote wouldn't create an instant pathway. Advisory committee recommendations are non-binding, and actually adding a substance to the Bulks List requires full notice-and-comment rulemaking, a process that takes years, not months ^[6]. So even in the best case for the seven peptides under review, nothing changes overnight. For retatrutide, which isn't even in that queue, there's no clock running at all. FDA maintains a public list of bulk drug substances nominated for compounding, sorted into interim categories, and you can check it yourself ^[7]. Retatrutide simply isn't there.

Does a "research use only" label make gray-market retatrutide legal to sell or acquire?

No, and FDA has said so in writing. Under 21 CFR 201.128, a product's "intended use" as a drug is established by labeling claims, advertising, and statements made by the seller, not by a disclaimer buried in the fine print ^[8]. If a company's marketing talks about weight loss, appetite suppression, or metabolic benefits, that's a drug claim, disclaimer or not. FDA acted on exactly this reasoning in a March 2026 warning letter to a peptide seller called Gram Peptides (MARCS-CMS 721806). FDA wrote that "despite such labelling, evidence from the company's website established that its products were intended to be drugs for human use," and the letter specifically named retatrutide as one of the products marketed on that site ^[9]. That's about as direct a signal as you'll get: labeling something "not for human consumption" doesn't insulate a seller if the surrounding marketing copy says otherwise, and it doesn't make your transaction lawful either. This matters for anyone weighing a vendor site's promises against the actual legal picture. A polished product page and a research disclaimer are not evidence of quality, purity, or legality. They're marketing. For more on how this specific legal exposure works for buyers and sellers, see retatrutide peptide buy.

What does personal importation policy say about ordering retatrutide from overseas?

FDA's personal importation policy is narrow, discretionary, and does not cover a drug like retatrutide. FDA publishes formal guidance on personal importation of unapproved drugs, and it's the rule that technically applies to anyone thinking about ordering an investigational compound from a supplier abroad ^[10]. The short version: FDA generally allows some enforcement discretion for personal imports of unapproved drugs in narrow circumstances, mainly involving serious conditions with no US-available treatment, small quantities for personal use, and no unreasonable risk. Retatrutide doesn't fit that profile in any way that would help a buyer. It's an investigational obesity/diabetes drug still being tested, and FDA-approved alternatives already exist for both indications (more on that below). Ordering it from an overseas peptide site is not a protected personal import; it's an unapproved new drug crossing into interstate or international commerce without an approved application, which is exactly what 21 U.S.C. 355 forbids ^[2].

What did retatrutide actually show in trials, and where can you verify it?

The headline number comes from a phase 2 obesity trial published in the New England Journal of Medicine: at the highest dose tested, 12 mg weekly by subcutaneous injection, participants lost a mean of 24.2 percent of body weight at 48 weeks, compared with 2.1 percent in the placebo group ^[11]. That's a real, peer-reviewed result, not a marketing claim, and it's the number driving most of the public interest in this drug. Mechanistically, retatrutide is a triple agonist, hitting the GIP, GLP-1, and glucagon receptors ^[11]. That's different from semaglutide, which works on GLP-1 alone, and different from tirzepatide, which works on GIP and GLP-1 but not glucagon. The third receptor target is the theoretical reason retatrutide has produced larger weight-loss numbers in early trials, though "theoretical" is doing real work in that sentence; mechanism doesn't automatically predict long-term outcomes or safety. You can verify the trial design yourself. The phase 2 obesity study is registered as NCT04881760, listed under its development code LY3437943, and the registration includes the specific dose arms and route studied ^[12]. Retatrutide has also been studied in registered type 2 diabetes trials ^[12], and it has moved into later-phase trials, including NCT05929066 ^[13] and NCT05882045 ^[14], which list current enrollment criteria, comparators, and endpoints. If you want dosing detail straight from the trial record rather than a vendor's dosing chart, those three registrations are the primary source. For a plain-language breakdown of what the phase 2 data shows dose by dose, see retatrutide peptide.

What retatrutide dose did trial participants actually receive, and can a doctor prescribe that?

In the phase 2 obesity trial, participants received weekly subcutaneous injections at several dose levels up to 12 mg, with the 24.2 percent weight-loss result tied specifically to the top dose at 48 weeks ^[11]. That's what the trial protocol used, under a formal investigational new drug application, with monitoring, informed consent, and a research infrastructure behind it. No clinician in ordinary practice can lawfully prescribe that dose, or any dose, of retatrutide outside a registered trial. There's no approved product to write a prescription for, no pharmacy that can legally dispense it, and no legal manufacturing supply chain feeding a US clinic. If you're offered a "retatrutide protocol" by a med spa, telehealth site, or online coach, that offer sits outside the law regardless of how the dosing numbers are framed. If you're trying to understand dosing science generally, including how weekly incretin-based injections are titrated, our retatrutide dosage chart and retatrutide dosage calculator walk through the trial protocols in detail, purely as reference material, not as instructions for self-administration.

What lawful, FDA-approved options exist instead of retatrutide?

Three approved incretin-based drugs are available right now through a normal prescription, with real safety data behind them. | Drug | Brand names | Mechanism | Approval status |

What should someone do while retatrutide is still unapproved?

Talk to a prescriber about the approved options that already exist, and treat weight management as a medical process rather than a peptide-sourcing project. NIDDK, the federal government's diabetes and digestive disease institute, publishes plain-language guidance on evidence-based weight management approaches, covering nutrition, physical activity, behavioral support, and when medication or surgery make sense . It's a useful neutral starting point if you're trying to sort real evidence from vendor marketing. If you specifically want access to retatrutide rather than an approved substitute, the only lawful route is enrollment in one of its ongoing clinical trials. ClinicalTrials.gov lists current, recruiting studies, and eligibility criteria are public information ^{[12] [13] [14]}. That's slower than getting a vial online, and you might not qualify or might be randomized to placebo, but it is the only pathway that doesn't involve breaking federal law or taking material of unknown purity and origin. Retatrutide Report exists to track this evidence as it develops: trial results, safety signals, and any change in retatrutide's regulatory status, including if it's ever formally nominated for the 503A Bulks List (something that, as of this writing, has never happened) ^{[6] [7]}.

What are the actual safety and quality risks of gray-market retatrutide?

Beyond the legal exposure, there's a practical quality problem: nothing requires gray-market retatrutide to be what the label says it is, at the purity or dose it claims, or free of contaminants. The certificate-of-analysis requirement in 503A exists precisely because unregulated bulk substances carry no guarantee of identity or purity ^[3], and research-use-only sellers are, by definition, operating outside that requirement. That means a buyer has no reliable way to know the actual dose in a vial, whether it's sterile, or whether it's retatrutide at all. Trial-grade material used in the NEJM study was manufactured and tested under investigational new drug controls ^[11]; a vial from an unregistered overseas supplier has none of that behind it. For a full breakdown of documented and theoretical side effects from the trial data itself, see retatrutide side effects, and for guidance on reconstitution risks specific to peptide handling, see how to reconstitute retatrutide. Both are written as reference material about trial-reported data, not as encouragement to source or self-administer unapproved product.

Frequently asked questions

Is it legal to obtain retatrutide in the US right now?

No. Retatrutide has no FDA approval ^[1], isn't on the 503A Bulks List ^[5], and has no USP monograph or approved reference product, so there's no legal pathway for a pharmacy to compound it or a seller to distribute it for human use. Any online offer to sell you retatrutide sits outside US drug law under 21 U.S.C. 355 ^[2].

What is the retatrutide price near me, and is it worth paying?

There's no lawful US price to quote, since no approved or legally compounded product exists. Gray-market listings vary widely in price, but price tells you nothing about legality, purity, or dose accuracy, and FDA has already flagged at least one seller's retatrutide marketing as establishing unlawful drug intent ^[12].

Can a compounding pharmacy legally make retatrutide?

No. Section 503A requires the substance to meet a USP/NF monograph, or be a component of an approved drug, or appear on the 503A Bulks List, in that order ^[4]. Retatrutide meets none of those conditions, and the current Bulks List has only six substances, none of them peptides ^[5].

Does a "research use only" label make retatrutide sales legal?

No. Under 21 CFR 201.128, intended use is judged by labeling claims, advertising, and seller statements, not disclaimers ^[11]. FDA's March 2026 warning letter to Gram Peptides found that a site's marketing established the product was intended as a human drug despite research-use labeling, and named retatrutide specifically ^[12].

Is retatrutide FDA-approved for weight loss or diabetes?

No. A Drugs@FDA search for retatrutide returns no approved product ^[1]. It remains investigational, studied in registered obesity and type 2 diabetes trials, but with no approved application under 21 U.S.C. 355, meaning it cannot legally enter interstate commerce for sale ^[2].

Has retatrutide been nominated for the 503A compounding Bulks List?

No. FDA's Pharmacy Compounding Advisory Committee reviewed seven other peptides (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, epitalon) in July 2026; retatrutide wasn't among them and has never been nominated ^[8]. Even a favorable vote wouldn't create a pathway without separate notice-and-comment rulemaking ^[9].

How much weight did retatrutide help people lose in trials?

In the phase 2 obesity trial published in NEJM, the 12 mg weekly dose produced a mean 24.2 percent weight reduction at 48 weeks, versus 2.1 percent for placebo ^[14]. That's the strongest published human data on retatrutide to date, from a registered trial (NCT04881760) ^[15].

What makes retatrutide different from semaglutide or tirzepatide?

Retatrutide is a triple agonist, acting on GIP, GLP-1, and glucagon receptors ^[14]. Semaglutide acts only on GLP-1; tirzepatide acts on GIP and GLP-1 but not glucagon. The added glucagon activity is the proposed mechanism behind retatrutide's larger early weight-loss results, though long-term comparative safety data isn't yet published.

Can I legally import retatrutide from another country for personal use?

Practically, no. FDA's personal importation policy allows narrow discretion for unapproved drugs treating serious conditions with no US alternative ^[13]. Retatrutide doesn't qualify: it's still investigational, and approved alternatives (semaglutide, tirzepatide, orforglipron) already exist ^{[3] [18]}, so there's no gap in available treatment that importation discretion would cover.

What FDA-approved drugs work similarly to retatrutide?

Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newly approved oral orforglipron (Foundayo, NDA 220934, six strengths from 0.8 to 17.2 mg) are all approved incretin-based options ^{[3] [18]}. None hits the glucagon receptor like retatrutide, but all have FDA-reviewed safety data and can be prescribed today.

How can I access retatrutide legally if I want to try it?

The only lawful route is enrollment in an active retatrutide clinical trial. ClinicalTrials.gov lists current studies with public eligibility criteria, including NCT04881760, NCT05929066, and NCT05882045 ^{[15] [16] [17]}. Outside a trial, no US clinician can prescribe it and no pharmacy can dispense it.

What dose of retatrutide did clinical trials use?

The phase 2 obesity trial tested weekly subcutaneous injections across several dose levels up to 12 mg, with the 24.2 percent weight-loss figure tied to the top dose at 48 weeks ^[14]. This is trial-reported data, not a prescribing recommendation, since no lawful prescription pathway currently exists outside that trial structure.

Sources

1. Drugs@FDA, FDA-approved drug products database: A search for the generic name retatrutide returns no FDA-approved product
2. 21 U.S.C. 355: A new drug cannot be introduced into interstate commerce without an approved application
3. 21 U.S.C. 353a(b)(1)(A)(i): The 503A compounding cascade requires a USP/NF monograph, or component of an approved drug, or Bulks List inclusion, in that order
4. 21 CFR 216.23, eCFR current through 2026-07-08: The final 503A Bulks List contains exactly six substances, none of them retatrutide or any peptide
5. 21 CFR 216.24: The separate 503B outsourcing facility bulks list also does not include retatrutide
6. Federal Register, Docket FDA-2025-N-6895, published 16 April 2026: FDA's Pharmacy Compounding Advisory Committee reviewed seven other peptides in July 2026; retatrutide was not among them and has never been nominated
7. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's public nominations list does not include retatrutide
8. 21 CFR 201.128: Intended use as a drug is established by labeling claims, advertising, and seller statements, not disclaimers
9. FDA, Personal Importation: FDA's personal importation policy sets narrow conditions for unapproved drug imports, which retatrutide does not meet
10. Jastreboff AM et al., New England Journal of Medicine, 2023: Phase 2 trial showed 24.2% mean weight loss at 12 mg dose at 48 weeks vs 2.1% placebo; retatrutide is a GIP/GLP-1/glucagon triple agonist
11. ClinicalTrials.gov NCT04881760: Registered phase 2 trial record lists dose arms, route, and that retatrutide has also been studied in type 2 diabetes trials
12. ClinicalTrials.gov NCT05929066: A later-phase retatrutide trial registration lists enrollment criteria, comparators, and endpoints
13. ClinicalTrials.gov NCT05882045: A second later-phase retatrutide trial registration provides an independent record of dosing and design
14. Drugs@FDA, FDA-approved drug products database (NDA 220934): Orforglipron was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg
15. NIDDK, Weight Management: NIDDK publishes federal guidance on evidence-based weight management approaches